Recent Updates
Recently added Catalysts
STXS Positive Sentiment

Stereotaxis to Participate in 20th Annual Craig-Hallum Institutional Investor Conference

Key Takeaway: Stereotaxis (NYSE: STXS) has announced that its CEO, David Fischel, will participate in the 20th Annual Craig-Hallum Institutional Investor Conference, scheduled for May 31, 2023. During the conference, Fischel will engage in one-on-one meetings with attendees to discuss the company's innovative technology and growth strategy. Stereotaxis is known for its advancements in surgical robotics for minimally invasive endovascular procedures, having treated over 100,000 patients globally.
Price reaction · baseline $2.11 (2023-05-24 close) · hit after-hours · clean, no other STXS news in the window
day 0 close
-0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prestigious investor conference enhances visibility.
  • CEO David Fischel expresses enthusiasm for sharing the company's strategy.
  • Stereotaxis is recognized as a leader in surgical robotics.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~8 mo
Medium dilution risk
Lead asset
Vdrive Lasso navigation, Manual Lasso navigation
Phase 3 · Atrial Fibrillation

Full Press Release Details

ST. LOUIS, May 25, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in Craig-Hallum’s 20th Annual Institutional Investor Conference.
Mr. Fischel will be available on Wednesday, May 31, 2023 for one-on-one meetings with conference attendees.
“We appreciate the invitation by Craig-Hallum and look forward to sharing Stereotaxis’ differentiated technology, clinical value, and growth strategy with investors,” says Mr. Fischel.
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com

Frequently Asked Questions

Who is participating in the 20th Annual Institutional Investor Conference?

David Fischel, Chairman and CEO of Stereotaxis, will participate in the conference.

When will the conference meetings with David Fischel take place?

Meetings with David Fischel are scheduled for Wednesday, May 31, 2023.

What is Stereotaxis known for?

Stereotaxis is known for pioneering surgical robotics for minimally invasive endovascular interventions.

How many patients have been treated using Stereotaxis technology?

Stereotaxis technology has treated over 100,000 patients globally.

What is the mission of Stereotaxis?

Stereotaxis aims to support robotic systems that enhance patient care and surgical precision.

Last updated: May 25, 2023